Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
J Pediatr ; 162(6): 1228-34, 1234.e1, 2013 Jun.
Article de Anglais | MEDLINE | ID: mdl-23324524

RÉSUMÉ

OBJECTIVES: To examine ammonia levels, pharmacokinetics, and safety of glycerol phenylbutyrate (GPB; also referred to as HPN-100) and sodium phenylbutyrate (NaPBA) in young children with urea cycle disorders (UCDs). STUDY DESIGN: This open label switch-over study enrolled patients ages 29 days to under 6 years taking NaPBA. Patients underwent 24-hour blood and urine sampling on NaPBA and again on a phenylbutyric acid-equimolar dose of GPB and completed questionnaires regarding signs and symptoms associated with NaPBA and/or their UCD. RESULTS: Fifteen patients (8 argininosuccinate lyase deficiency, 3 argininosuccinic acid synthetase deficiency, 3 ornithine transcarbamylase deficiency, 1 arginase deficiency) ages 2 months through 5 years enrolled in and completed the study. Daily ammonia exposure (24-hour area under the curve) was lower on GPB and met predefined noninferiority criteria (ratio of means 0.79; 95% CI 0.593-1.055; P=.03 Wilcoxon; 0.07 t test). Six patients experienced mild adverse events on GPB; there were no serious adverse events or significant laboratory changes. Liver tests and argininosuccinic acid levels among patients with argininosuccinate lyase deficiency were unchanged or improved on GPB. Eleven of 15 patients reported 35 symptoms on day 1; 23 of these 35 symptoms improved or resolved on GPB. Mean systemic exposure to phenylbutyric acid, phenylacetic acid, and phenylacetylglutamine (PAGN) were similar and phenylacetic acid exposure tended to be higher in the youngest children on both drugs. Urinary PAGN concentration was greater on morning voids and varied less over 24 hours on GPB versus NaPBA. CONCLUSIONS: GPB results in more evenly distributed urinary output of PAGN over 24 hours were associated with fewer symptoms and offers ammonia control comparable with that observed with NaPBA in young children with UCDs.


Sujet(s)
Ammoniac/sang , Substitution de médicament , Glycérol/analogues et dérivés , Foie/physiopathologie , Phénylbutyrates/administration et posologie , Anomalies congénitales du cycle de l'urée/traitement médicamenteux , Enfant , Enfant d'âge préscolaire , Femelle , Glutamine/analogues et dérivés , Glutamine/urine , Glycérol/administration et posologie , Glycérol/effets indésirables , Humains , Nourrisson , Mâle , Phénylbutyrates/effets indésirables , Enquêtes et questionnaires , Anomalies congénitales du cycle de l'urée/sang , Anomalies congénitales du cycle de l'urée/urine
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE